FDA Output, November 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in November 2026. Updated November 9.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in November 2026. Updated November 9.
Singapore possesses many of the capabilities needed to build successful medtech companies. MedTech Catapult, a national platform hosted by the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, aims to connect and build upon these strengths to accelerate promising innovations toward commercial success, and, in the process, to further strengthen Singapore’s medtech ecosystem.
Recor Medical is expanding access to its ultrasound renal denervation technology with the help of Medicare coverage, professional guidelines, and clinical results supporting renal denervation for the treatment of drug-resistant hypertension. Excerpted from our recent feature “Renal Denervation Winds Shift in Recor’s Favor.”